SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-019641
Filing Date
2023-05-09
Accepted
2023-05-09 16:08:26
Documents
14
Period of Report
2023-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K janx-20230509.htm   iXBRL 8-K 63371
2 EX-99.1 janx-ex99_1.htm EX-99 196175
3 GRAPHIC img201480580_0.jpg GRAPHIC 4603
  Complete submission text file 0000950170-23-019641.txt   403196

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT janx-20230509_lab.xml EX-101.LAB 14743
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT janx-20230509_pre.xml EX-101.PRE 11925
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT janx-20230509.xsd EX-101.SCH 2461
8 EXTRACTED XBRL INSTANCE DOCUMENT janx-20230509_htm.xml XML 5113
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 23902006
SIC: 2834 Pharmaceutical Preparations